ERBB2 and ovarian carcinoma: Molecular classifications have been used to broadly divide ovarian cancer as Type I (mutations in KRAS and BRAF leading to activation of the MAPK pathway) or as Type II (extensive TP53 mutations, and sometimes over expression of HER2/neu and AKT2) [4,5] tumours.